These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6539304)

  • 1. Tissue type plasminogen activator, but not urokinase, exerts transformation-enhancing activity.
    De Petro G; Vartio T; Salonen EM; Vaheri A; Barlati S
    Int J Cancer; 1984 May; 33(5):563-7. PubMed ID: 6539304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transformation-enhancing activity of gelatin-binding fragments of fibronectin.
    De Petro G; Barlati S; Vartio T; Vaheri A
    Proc Natl Acad Sci U S A; 1981 Aug; 78(8):4965-9. PubMed ID: 6458038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells.
    Quigley JP; Gold LI; Schwimmer R; Sullivan LM
    Proc Natl Acad Sci U S A; 1987 May; 84(9):2776-80. PubMed ID: 3033662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformation-dependent activation of urokinase-type plasminogen activator by a plasmin-independent mechanism: involvement of cell surface membranes.
    Berkenpas MB; Quigley JP
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7768-72. PubMed ID: 1652763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of fibronectin mRNA by urokinase- and tissue-type plasminogen activator in human skin fibroblasts: differential role of u-PA and t-PA at the fibronectin protein level.
    De Petro G; Tavian D; Marchina E; Barlati S
    Biol Chem; 2002 Jan; 383(1):177-87. PubMed ID: 11928812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator.
    Jankun J; Maher VM; McCormick JJ
    Cancer Res; 1991 Feb; 51(4):1221-6. PubMed ID: 1847659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts.
    De Petro G; Copeta A; Barlati S
    Exp Cell Res; 1994 Jul; 213(1):286-94. PubMed ID: 8020601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasminogen activator is an apparent lymphocyte mitogen.
    Cohen SD; Israel E; Spiess-Meier B; Wainberg MA
    J Immunol; 1981 Apr; 126(4):1415-20. PubMed ID: 6259259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced plasminogen activator production of Syrian hamster embryo cells transformed by chemicals or the c-Ha-ras oncogene: type of plasminogen activators involved and their contribution to the transformed phenotype.
    de Kok AJ; Sips H; Chang GT; Verheijen JH
    Carcinogenesis; 1989 Jul; 10(7):1155-61. PubMed ID: 2500266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y; Scully MF; Ellis V; Kakkar VV
    Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET; Mack DL; Sobel BE
    Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.
    Pöllänen J; Saksela O; Salonen EM; Andreasen P; Nielsen L; Danø K; Vaheri A
    J Cell Biol; 1987 Apr; 104(4):1085-96. PubMed ID: 3104349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.
    Nielsen LS; Grøndahl-Hansen J; Andreasen PA; Skriver L; Zeuthen J; Danø K
    J Immunoassay; 1986; 7(3):209-28. PubMed ID: 3091639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator is a mitogen for astrocytes in developing cerebellum.
    Moonen G; Grau-Wagemans MP; Selak I; Lefebvre PP; Rogister B; Vassalli JD; Belin D
    Brain Res; 1985 May; 352(1):41-8. PubMed ID: 4039964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The RH-PA cell line--a source for obtaining the urokinase-type plasminogen activator].
    Kapina MA; Zelenin MG; Glukhova LA; Egorov BB
    Antibiot Khimioter; 1989 Dec; 34(12):893-8. PubMed ID: 2517003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.
    Bode C; Runge MS; Schönermark S; Eberle T; Newell JB; Kübler W; Haber E
    Circulation; 1990 Jun; 81(6):1974-80. PubMed ID: 2111744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.